Abstract
From Kaiser Permanente Southern California Region, San Diego, Pasadena, Harbor City, Los Angeles, and Orange County, Calif. E-mail: robert.s.zeiger@kp.org. The study was supported by an investigational grant to the Southern California Permanente Medical Group Research and Evaluation Department from Aerocrine AB, Solna, Sweden, and Panasonic Shikoku Electronics Co, Ltd, T~oon City, Ehime, Japan, with protocol development, data collection, extraction, analyses, and manuscript preparation done by investigators. Disclosure of potential conflict of interest: R. S. Zeiger is a consultant for AstraZeneca, Aerocrine, Genentech, GlaxoSmithKline, Novartis, Merck, Schering Plough, MedImmune, and Sunovion and has received research support from Aerocrine, Genentech, GlaxoSmithKline, Merck, AstraZeneca, and TEVA. M. Schatz is a consultant for Amgen, Merck, and GlaxoSmithKline and has received research support from Aerocrine, Genentech, Merck, and GlaxoSmithKline. M. S. Kaplan has received research support from Genentech and Aerocrine and is on the Asthma and Allery Foundation of America (AAFA) California Board of Directors. The rest of the authors have declared that they have no conflict of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
